1)Lane DP. Cancer. p53, guardian of the genome. Nature 358 : 15-16, 1992
2)Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature 387 : 296-299, 1997
3)Bosman FT, Carneiro F, Hruban RH, et al(eds). WHO Classification of Tumours of the Digestive System, 4th ed. IARC, Lyon, 2010
4)Yao T, Utsunomiya T, Nagai E, et al. p53 expression patterns in colorectal adenomas and early carcinomas : A special reference to depressed adenoma and non-polypoid carcinoma. Pathol Int 46 : 962-967, 1996
5)Yukawa M, Fujimori T, Maeda S, et al. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut 35 : 1258-1261, 1994
6)Fujii S, Fujimori T, Chiba T. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia. J Exp Clin Cancer Res 22 : 107-115, 2003
7)Kaserer K, Schmaus J, Bethge U, et al. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 190 : 450-456, 2000
8)Kressner U, Inganäs M, Byding S, et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17 : 593-599, 1999
9)Tachibana M, Kawamata H, Fujimori T, et al. Dysfunction of p53 pathway in human colorectal cancer : analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2. Int J Oncol 25 : 913-920, 2004
10)Horiuchi H, Kawamata H, Omotehara F, et al. Negative immunohistochemical staining of p53 protein does not always reflect wild-type p53 gene in cancer cells. J Gastroenterol 39 : 801-803, 2004
11)Suehiro Y, Wong CW, Chirieac LR, et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and p53 pathways in colorectal carcinoma. Clin Cancer Res 14 : 2560-2569, 2008